Prothena Corporation PLC (NASDAQ:PRTA)‘s stock had its “buy” rating reissued by equities researchers at SunTrust Banks, Inc. in a report released on Monday, October 2nd. They currently have a $75.00 price objective on the biotechnology company’s stock. SunTrust Banks, Inc.’s price objective suggests a potential upside of 23.46% from the stock’s previous close.

Several other equities research analysts also recently issued reports on the stock. Royal Bank Of Canada restated a “buy” rating on shares of Prothena Corporation PLC in a research note on Friday, September 29th. BTIG Research decreased their price target on shares of Prothena Corporation PLC from $80.00 to $77.00 and set a “buy” rating on the stock in a research note on Friday, September 29th. Cantor Fitzgerald reiterated a “buy” rating and set a $79.00 price target on shares of Prothena Corporation PLC in a research note on Thursday, September 28th. ValuEngine raised Prothena Corporation PLC from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, Evercore ISI started coverage on Prothena Corporation PLC in a report on Wednesday, August 16th. They issued an “outperform” rating and a $83.00 price target for the company. One analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $78.58.

Prothena Corporation PLC (NASDAQ PRTA) traded up 1.15% during midday trading on Monday, reaching $60.75. 161,453 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $62.49 and its 200-day moving average price is $57.56. Prothena Corporation PLC has a 1-year low of $40.58 and a 1-year high of $70.00. The company’s market capitalization is $2.33 billion.

Prothena Corporation PLC (NASDAQ:PRTA) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.43. The company had revenue of $26.81 million for the quarter, compared to the consensus estimate of $16.08 million. Prothena Corporation PLC had a negative return on equity of 33.20% and a negative net margin of 527.56%. The company’s revenue for the quarter was up 7951.1% compared to the same quarter last year. During the same quarter last year, the company posted ($1.18) earnings per share. Equities analysts expect that Prothena Corporation PLC will post ($4.41) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “SunTrust Banks, Inc. Reaffirms “Buy” Rating for Prothena Corporation PLC (NASDAQ:PRTA)” was originally published by Marea Informative and is the sole property of of Marea Informative. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at http://www.mareainformativa.com/prothena-corporation-plc-prta-rating-reiterated-by-suntrust-banks-inc/114922/.

In other news, Director Dennis J. Selkoe sold 3,500 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $64.17, for a total transaction of $224,595.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Tara Nickerson sold 17,500 shares of the stock in a transaction on Monday, September 25th. The shares were sold at an average price of $63.60, for a total value of $1,113,000.00. Following the completion of the sale, the insider now owns 19,500 shares in the company, valued at approximately $1,240,200. The disclosure for this sale can be found here. Insiders sold a total of 34,424 shares of company stock worth $2,247,237 in the last 90 days. Company insiders own 3.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Principal Financial Group Inc. grew its holdings in Prothena Corporation PLC by 1.2% in the 1st quarter. Principal Financial Group Inc. now owns 6,528 shares of the biotechnology company’s stock valued at $364,000 after buying an additional 77 shares in the last quarter. OMERS ADMINISTRATION Corp grew its holdings in shares of Prothena Corporation PLC by 2.0% during the 2nd quarter. OMERS ADMINISTRATION Corp now owns 5,000 shares of the biotechnology company’s stock worth $271,000 after purchasing an additional 100 shares in the last quarter. Bank of Montreal Can grew its holdings in shares of Prothena Corporation PLC by 6.7% during the 2nd quarter. Bank of Montreal Can now owns 1,858 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 117 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of Prothena Corporation PLC by 1.0% during the 2nd quarter. ProShare Advisors LLC now owns 22,910 shares of the biotechnology company’s stock worth $1,240,000 after purchasing an additional 216 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of Prothena Corporation PLC by 8.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,249 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 250 shares in the last quarter.

About Prothena Corporation PLC

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Analyst Recommendations for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Stock Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related stocks with our FREE daily email newsletter.